Clinical Trial

A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A18 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D). A secondary purpose To preliminarily evaluate the anti-tumor efficacy of SIBP-A18. Evaluate the effect of SIBP-A18 injection on Q to T interval/Corrected QT interval (QT/QTc interval) in participants with advanced solid tumors
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-14; most recent amendment 2026-01-05.
Status change: Not Yet Recruiting → Recruiting 2026-01-05
Trial Details
NCT Number NCT06985368
Lead Sponsor Shanghai Institute Of Biological Products
Conditions Solid Tumor Malignancy
Enrollment 156 participants
Start Date 2025-06-16
Primary Completion 2028-05-15 (estimated)
Study Completion 2028-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-07